Technical Analysis for INBX - Inhibrx, Inc.

Grade Last Price % Change Price Change
C 38.12 13.35% 4.49
INBX closed up 13.35 percent on Tuesday, January 19, 2021, on 40 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Up Up
Historical INBX trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
180 Bullish Setup Bullish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
Wide Bands Range Expansion 13.35%
20 DMA Resistance Bearish 5.89%
Bearish Engulfing Bearish 5.89%
Outside Day Range Expansion 5.89%
Wide Bands Range Expansion 5.89%
20 DMA Resistance Bearish -1.68%
MACD Bullish Centerline Cross Bullish -1.68%
Older End-of-Day Signals for INBX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above 20 DMA about 11 hours ago
10 DMA Support about 14 hours ago
60 Minute Opening Range Breakout about 14 hours ago
Rose Above Previous Day's High about 14 hours ago
20 DMA Resistance about 14 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Inhibrx, Inc. Description

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a multivalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcomas; and INBRX-105, an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc-fusion protein-based therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency; and INBRX-103, a mAb in Phase 1 clinical trials that targets cluster of differentiation 47. Its preclinical programs include INBRX-106, a sdAb-based hexavalent agonist of OX40 for a range of oncology indications; and INBRX-111, a multi-functional antibody that targets Pseudomonas aeruginosa. The company was founded in 2010 and is headquartered in La Jolla, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pharmaceutical Industry Solid Tumors Clinical Research Clinical Trial Tumors Sarcoma Fusion Protein Antitrypsin Deficiency Pseudomonas Pseudomonas Aeruginosa Sarcomas

Is INBX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 50.97
52 Week Low 15.2
Average Volume 114,474
200-Day Moving Average 0.00
50-Day Moving Average 32.57
20-Day Moving Average 37.81
10-Day Moving Average 34.79
Average True Range 4.03
ADX 22.7
+DI 21.43
-DI 19.96
Chandelier Exit (Long, 3 ATRs ) 38.89
Chandelier Exit (Short, 3 ATRs ) 40.23
Upper Bollinger Band 48.90
Lower Bollinger Band 26.72
Percent B (%b) 0.51
BandWidth 58.67
MACD Line 0.22
MACD Signal Line 0.60
MACD Histogram -0.3845
Fundamentals Value
Market Cap 1.44 Billion
Num Shares 37.7 Million
EPS
Price-to-Sales 104.68
Price-to-Book 11.84
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 43.40
Resistance 3 (R3) 42.85 40.53 42.52
Resistance 2 (R2) 40.53 39.19 40.81 42.23
Resistance 1 (R1) 39.33 38.36 39.93 39.88 41.93
Pivot Point 37.01 37.01 37.32 37.29 37.01
Support 1 (S1) 35.81 35.67 36.41 36.36 34.31
Support 2 (S2) 33.49 34.84 33.77 34.01
Support 3 (S3) 32.29 33.49 33.72
Support 4 (S4) 32.84